we are fortunate to assemble a unique multidisciplinary team allowing a collaborative effort in the intersection of neuroscience, nanotechnology, information technology, and entrepreneurship
MAX SIGNAEVSKY, MD, PHD
neuroscience / neuropathology
Dr. Signaevsky received his MD in 1993 from the Medical Military Academy in St. Petersburg, Russia. His medical research passion led to a PhD thesis originated in Erasmus University Rotterdam and defended in Petrov Research Institute of Oncology, St. Petersburg, in 1999. Max continued his research career at the Prostate Center in Vancouver, Canada. In 2005 he moved to New York and assumed the position of Assistant Professor at SUNY Downstate Medical Center. In 2016, Max graduated the Neuropathology training program from the University of British Columbia in Vancouver, followed by a fellowship in Neuropathology of Neurodegenerative diseases.
In 2016, Max returned to New York where he is an Scientist/Instructor and a Brain Bank Fellow at Icahn School of Medicine at Mount Sinai, Friedman Brain Institute. He is a recipient of a Career Development Award from NIH/NIA (2017.)
IGOR YAROSLAVSKY, PHD
chemistry / nanotechnology
Dr. Yaroslavsky obtained his Masters in Chemical Engineering in 1980. In 1987, he defended his PhD in Applied Sciences, with the PhD thesis: "Hydro thermal crystal growth of the piezoelectric crystals" at the Mendeleyev University of Chemical Technology, Moscow. He graduated the post-doctoral research program at Crystal Growth and Nuclear Spectroscopy Laboratory at the Hebrew University of Jerusalem, Israel, and subsequently assumed the position of Assistant Research Professor at the same university. In 1996 Igor accepted a Research Associate position at Simon Fraser University, British Columbia, where he developed a multi-crystalline thin layer deposition technology for the semiconductor industry. In 2002, he joined Northwest Mettech Corporation as a Senior Research Chemical Engineer. Igor has authored 32 peer-reviewed publications and holds 12 US and international patents.
OPHIR AUSLAENDER, PHD
physics / nanotechnology
Dr. Auslaender is a physicist specializing in nanoscale device fabrication. He has worked on novel oxides, semiconductors, magnetic, organic and piezoelectric materials. Dr. Auslaender was a physics professor at the Technion – Israel Institute of Technology, where he headed a research group, supervised graduate students and published papers.
PhD (Chemistry, Nanotechnology)
Dr. Jurow received his Ph.D. in 2012 from the City University of New York and has since continued to develop novel nanoscale electronic devices at the Brookhaven National Labs, Lawrence Berkeley National Lab, UC Berkeley, and USC. His research spans a broad range of photonic and theranostic materials and devices. He has exceptional expertise in the design of new organic, polymeric, inorganic and nanoparticulate materials with carefully tuned nanoscale architectures to optimize performance in optoelectronics and other functional devices. He has published regularly in the premier journals in his filed.
JOHN G. KRAL, MA, MD, PHD, FACS
Dr. Kral received his MA in Education and Behavioral Neuroscience in 1961, his MD in 1967, completed surgical residency in 1972 and defended his PhD thesis, “Surgical reduction of Adipose Tissue”, in 1976 at the University of Göteborg, Sweden. In 1988 Dr. Kral came to Downstate as Professor of Surgery and Director of Surgical Services at KCHC. In 1991, he initiated and co-organized the NIH Consensus Development Conference, “Gastrointestinal Surgery
for Severe Obesity”. He served as President of the NY State Society of Surgeons 1995-7, was co-chairman of the NIH Workshop, “Research Considerations in Obesity Surgery”, in 2001 and has served on numerous scientific organizing committees, editorial boards, and scientific societies. As Professor of Surgery and Medicine, and faculty member of the School of Graduate Studies, Dr. Kral was a standing member of the Downstate Institutional Review Board and the Credentials Committee.
Dr. Kral has published over 50 chapters and reviews and more than 100 peer-reviewed papers in high impact
journals. His research interests included: Brain implants, Neuro-modulation, Central and Autonomic Nervous
Systems, Cognitive function, Molecular genetics, Rehabilitation and many more.
Dr. John G. Kral, our advisor, a mentor, and a friend, succumbed unexpectedly to a brief and serious illness on Wednesday, June 19th, 2019.
MARK STEWART, MD, PHD
Dr. Stewart currently serves as professor in the Departments of Physiology, Pharmacology and Neurology, Dean of the School for Graduate Studies and Vice Dean for Research at SUNY Downstate Medical Center in New York, NY. Dr. Stewart is an accomplished academician, researcher, and administrator with proven leadership skills and a deep understanding of both Downstate and SUNY academic strengths and regulations. Dr. Stewart received his MD and PhD degrees in 1991 from Downstate. His PhD and a postdoctoral fellowship were in Neuroscience, and his current research is focused on the systemic consequences of epileptic seizure activity including sudden death. His lab has developed a unique animal model that has permitted the most complete understanding of autonomic, cardiovascular, and respiratory pathophysiology during seizures and suggested the mechanism for sudden death in epilepsy. This work has led to the development of several technologies to prevent death or resuscitate patients, including a vagus nerve stimulation-based cardioverter/defibrillator that received funding from SUNY’s Technology Accelerator Fund. Dr. Stewart joined the Physiology faculty in 1994 and was promoted through the ranks to a tenured professor in 2008. He was appointed Dean of the School of Graduate Studies and Vice Dean for Research in 2009. He has played major roles in establishing an MD/PhD Program in Nanomedicine with the SUNY Polytechnic Institute, a PhD Track in Developmental Neuroscience in partnership with the Institute for Basic Research in Developmental Disabilities in Staten Island, and numerous other research training and pipeline programs with area universities, including the first major research training grant for CUNY Medgar Evers College.
YANA BROMBERG, PHD
Dr. Yana Bromberg is an Associate Professor in the Department of Biochemistry and Microbiology and Adjunct Professor in the Department of Genetics at Rutgers University.
She is also a fellow at the Institute of Advanced Studies in the Technical University of Munich.
Dr. Bromberg has Bachelors degrees in Biology and Computer Sciences from SUNY Stony Brook and a Ph.D. in Biomedical Informatics from Columbia University.
She has over 15 years of experience in developing clinically relevant methods and tools in the bioinformatics/biotech space and has co-authored over 50 peer reviewed scientific articles.
Her work has been recognized by the NSF CAREER Award, the PhRMA Foundation Young Investigator Research Starter Award, and the Hans-Fischer Award for outstanding early career scientists, among many others.
Dr. Bromberg serves as an editor and reviewer of several top journals and is one of the Directors of the International Society for Computational Biology (ISCB).
Irina holds a BS in finance from Rutgers University School of Business, and an MBA from the Stern School of Business, New York University. Irina spent first 15 years of her career investing across traditional and alternative asset classes. Currently, she is a Chief Operating Officer at HomeoLux, a wellness device startup. Prior to HomeoLux, Irina was a Director of Investment Research at Artivest, where she was responsible for investment due diligence of private equity, private credit, and hedge funds. Previously, at The Juilliard School, she focused on evaluating and monitoring investment managers for the School’s $1 bln endowment. Prior to Juilliard, Irina was an alternative investments analyst at the YMCA Retirement Fund supporting the Fund’s private equity, real estate and energy programs. She started her career at Metropolitan Life Insurance, working in private equity, capital markets, and international investments.
Leo Grzhonko is a graduate of UC Berkeley in Economics and Harvard Business School. He is Founder and CEO of MonDevices, a health technology company which manufactures MonBaby, an award winning movement monitor sold around the world. Prior to MonBaby, Leo was a Founder and President of AdoTube - a technology company that sold to Exponential Interactive in 2011. Before moving into the private sector, Leo worked on Wall Street in equity and fixed income derivatives in the late 1990's. He has also been a partner and board member of several start up technology companies, including many in the Pharma and Biotech space. He has a portfolio of angel investments, with several successful exits, and over a decade of experience helping new technology companies grow.